Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYB | P10242 | 18/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4331540 | 0.90 | MYB (0.87) | MYB | |
| SCHEMBL4327922 | 0.89 | MYB (0.83) | MYB | |
| SCHEMBL12136727 | 0.89 | MYB (0.75) | MYB | |
| SCHEMBL20368770 | 0.87 | MYB (0.72) | MYB | |
| SCHEMBL4335346 | 0.86 | MYB (1.00) | MYB | |
| SCHEMBL4319474 | 0.86 | MYB (0.58) | MYB | |
| SCHEMBL8543671 | 0.84 | MYB (1.00) | MYB | |
| SCHEMBL5959389 | 0.83 | TUBB4A (0.82) | MYB | |
| SCHEMBL4339420 | 0.83 | TUBB4A (0.56) | MYB | |
| SCHEMBL5959349 | 0.83 | TUBB4A (0.82) | MYB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1230232-B1 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2004-02-25 | — | — | EP | claimed |
| EP-1230232-A2 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2002-08-14 | — | — | EP | claimed |
| WO-2001034591-A2 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2001-05-17 | — | — | WO | claimed |
| EP-2638025-B1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM DKFZ (DE) | 2020-02-05 | — | — | EP | disclosed |
| US-20180334442-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | Ruprecht-Karls-Universität Heidelberg (DE) | 2018-11-22 | — | — | US | disclosed |
| US-10065939-B2 | Chromene derivatives and their analogs as Wnt pathway antagonists | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2018-09-04 | — | — | US | disclosed |
| EP-2638026-B1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM DKFZ (DE) | 2018-07-11 | — | — | EP | disclosed |
| US-20160355496-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-12-08 | — | — | US | disclosed |
| US-20160355496-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-12-08 | — | — | US | disclosed |
| US-20160355496-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-12-08 | — | — | US | disclosed |
| US-9371333-B2 | Chromene derivatives and their analoga as Wnt pathway antagonists | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-06-21 | — | — | US | disclosed |
| US-20130296344-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) | 2013-11-07 | — | — | US | disclosed |
| WO-2012062905-A2 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ) (DE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062901-A2 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ) (DE) | 2012-05-18 | — | — | WO | disclosed |
| US-7507762-B2 | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20050154015-A1 | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2005-07-14 | — | — | US | disclosed |
| US-6906203-B1 | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1230232-B1 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2004-02-25 | — | — | EP | disclosed |
| EP-1230232-A2 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001034591-A2 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154015-A1 | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP4, CASP3, CASP5 | MYB 429/4885 |
| US-20160355496-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | WNT3, WNT1, WNT3A | MYB 152/4885 |
| US-10065939-B2 | Chromene derivatives and their analogs as Wnt pathway antagonists | WNT3, WNT1, WNT3A | MYB 152/4885 |
| US-20130296344-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | WNT3, WNT1, WNT3A | MYB 172/4885 |
| US-20180334442-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | WNT3, WNT1, WNT3A | MYB 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.